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Abstract: The precise role of estrogen in the pathogenesis of pelvic organ prolapse (POP) is still unclear, while
the results concerning the effect of selective estrogen receptor modulators on pelvic organ prolapse are contra-
dictory. Our aim was to test whether alteration in the expression of estrogen receptors in the pelvic floor of pre-
and post-menopausal women is related to genital prolapse status. The mRNA levels of ERa and ERb in 60
biopsy specimens were measured. Significantly higher expression of ERa and higher ERa/ERb ratio were dem-
onstrated in post-menopausal women compared to pre-menopausal women. Higher expression of ERa and
higher ERa/ERb ratio were detected in all studied groups with POP, thus it did not reach significance in the
post-menopausal group. Pre-menopausal and post-menopausal women presenting pelvic organ prolapse had no
difference in the ERa expression. Our preliminary study may indicate that pelvic organ prolapse is associated
with higher expression of ERa/ERb in the pelvic floor of both pre- and post-menopausal women; thus not
reaching statistical significance in the post-menopausal women was probably due to the group’s size. We believe
that the inevitable changes in the estrogen receptor expression over women’s different lifetimes may affect the
risk of genital prolapse progression, and might contribute to the further search for appropriate selective estro-
gen receptor modulators as a treatment for women with pelvic organ prolapse. (Folia Histochemica et Cytobio-
logica 2011; Vol. 49, No. 3, pp. 521–527)
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Introduction
Pelvic organ prolapse (POP) can be observed in
women whose tissues and muscles holding their pel-
vic organs have stretched or weakened. Epidemio-
logic data suggests that a woman’s lifetime risk for
undergoing prolapse reconstructive surgery is ap-
proximately 11% by the age of 80 [1]. In addition,
30% of women will undergo multiple procedures for
POP repair [1, 2].
Observational and clinical studies have demon-
strated that pelvic organ prolapse is diagnosed most
frequently in post-menopausal women and there is
significant evidence that the condition is mainly re-
lated to pregnancy and labor [3]. Nevertheless, POP
has also been recorded in virginal and nulliparous
women, and can be caused by other factors which
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might increase abdominal pressure such as: obesity,
chronic cough and constipation as well as prior pel-
vic surgery and connective tissue disorders [4, 5].
The current knowledge of the pathophysiology of
POP is still scanty. Since pelvic organ prolapse can
also appear in pre-menopausal and nulliparous wom-
en, one could suggest the role of the quality of con-
nective tissue of the pelvic supportive structures in
the development of POP. On the other hand, there is
strong evidence that hypoestrogenic state may con-
tribute to the development of prolapse, since the prev-
alence of POP is mainly in the post-menopausal peri-
od [4]. The precise role of estrogens in the pathogen-
esis of the pelvic organ prolapse is still unknown. Sev-
eral publications which have studied the effect of
estrogen and Selective Estrogen Receptor Modula-
tors (SERMs) on POP, have been inconsistent. In
some studies, raloxifene and tamoxifen appeared to
worsen the prolapse when compared with conjugat-
ed equine estrogen and placebo [6, 7]. In other stud-
ies, the protective influence of raloxifene on the de-
velopment of POP after nine months of therapy and
a 50% reduction of the surgical intervention risk in
post-menopausal women have been reported [8]. Fur-
thermore, SERMs such as levormeloxifene and idox-
ifene have been found to increase the risk of pelvic
organ prolapse and POP was reported as an adverse
event associated with both drugs [9, 10].
The aim of our study was to test whether alter-
ation in the expression of estrogen receptors in the
pelvic floor of pre-menopausal and post-menopausal
women is related to pelvic organ prolapse status, and
whether it can shed light on the contradictory re-
sults obtained from different studies with SERMs.
We quantified the mRNA levels of both forms of
estrogen receptors, a and b (ERa and ERb), in the
vesico-vaginal and recto-vaginal walls of the pelvic
floor in relation to menopausal status and the pres-
ence of POP.
Material and methods
The regional ethical committee (Comité de Protection des
Personnes Ile de France X) approved the study. Sixty biop-
sy specimens from pelvic floor tissues were obtained from
30 patients categorized into four groups. Group 1: pre-
-menopausal women with POP (n = 4, mean age 40.7 ± 6.0
years), group 2: pre-menopausal women without POP (n = 5,
mean age 47.3 ± 3.0 years), group 3: post-menopausal wom-
en with POP (n = 12, mean age 62.9 ± 8.2 years) and group
4: post-menopausal women without POP (n = 9, mean age
65.0 ± 12.2 years). The quantification of the mRNA levels
of estrogen receptors (ERs) was carried out in samples of
connective tissue obtained at the upper third of the vesico-
vaginal and recto-vaginal walls from patients undergoing
hysterectomy or surgery for prolapse and were examined
also by pathologists. Samples were deep frozen in liquid ni-
trogen and stored until RNA extraction.
The RNA was isolated according to Chomczynski’s pro-
tocol [11]. ERa and ERb mRNAs were measured by quan-
titative assays based on Reverse Transcription (RT) of the
mRNA and real-time Polymerase Chain Reaction (PCR)
amplification of the cDNA. Using the RT-PCR technique,
mRNA of both ERs was successfully detected in the vesico-
vaginal fascia tissue and recto-vaginal fascia tissue.
Preparation of real-time PCR mix. All of the PCR reac-
tions were performed with an ABI Prism 7700 Sequence
Detection System (Applied Biosystems, Los Angeles, CA,
USA). PCR was performed using the Taqman Reagents kit.
The amplification reactions were performed in a 30-μL fi-
nal volume containing 5 μl cDNA, 15 μl Taqman Probe Bio-
rad. Final ERa, ERb, Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) forward and reverse primer concen-
trations are listed in Table 1.
Real-time RT-PCR and temperature profiles. The real-
-time RT-PCR protocol used for quantification of ERa, ERb
was as follows: initial denaturation: 94°C for 10 minutes;
annealing and elongation: 94°C for 60 seconds; 65°C for 60
seconds; 72°C for 45 seconds; repeated 30 times with addi-
tional 10 min extension for the last cycle.
Relative gene expression quantification. The value of
termed cycle threshold (Ct) was determined by the number
of the first cycle at which fluorescence was greater than the
set threshold value. The average Ct of duplicate samples
was calculated. The quantities of the studied ER transcripts
were calculated using the standard curves for ERa or ERb
and normalized by the level of GAPDH mRNA and by cor-
rection factors: 10–2 and 10–3 for the ERa and ERb expres-
sions respectively.
Statistical analysis. Since the expressions of ERa and ERb
were non-normally distributed, the studied variables were
expressed as median and 1–3 quartile range. The differenc-
es between the groups were compared by Mann–Whitney
U test using the Statistica 5.1 program (Statsoft 5.1, Tulsa,
OK, USA). The results were considered significant when
p values were lower than 0.05.
Results
The expression of both ERa and ERb were detected
in all 60 investigated tissues. The comparison of the
ERs expression and the ERa/ERb ratio in the stud-
ied tissues between the groups and with relation to
POP status is detailed in Table 2. When we compared
the ERs expression between pre-menopausal and
post-menopausal patients, there was a significantly
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higher expression of ERa and higher ERa/ERb ratio
in post-menopausal women. Higher expression of
ERa and higher ERa/ERb ratio were detected in all
studied groups with POP, thus it did not reach signif-
icance in the post-menopausal group. Pre-menopausal
women presenting POP had in addition lower expres-
sion of ERb compared to pre-menopausal women
without POP. Figures 1–3 demonstrate the ERa and
ERb expression in connective tissue of vesico-vagi-
nal and recto-vaginal fascias (median, 1–3 quartile)
in pre-menopausal women (Figure 1), in post-meno-
pausal women (Figure 2), and in all studied groups
(Figure 3) with versus without POP. The comparison
of ERa/ERb ratio in women with versus without POP
in pre- and post-menopausal women and in all stud-
ied groups is presented in Figure 4.
After stratification by POP status, a significant
difference in the expression of ERa between pre-
-menopausal and post-menopausal patients were still
observed in women without prolapse (p = 0.032). In
Table 1. Oligonucleotide primer sequences of estrogen receptors and GAPDH for real-time quantitative RT-PCR
Gene Sequences (5' Æ 3') Final concentration (pM)
GAPDH* F: ATT CCA CCC ATG GCA AAT 0.33
R: GGC AGA GAT GAT GAC CCT TT 0.33
ERa† F: TGC TTC AGG CTA CCA TTA TGG AGT CTG 3.75
R: GTC AGG GAC AAG GCC AGG CTG 3.75
ERb†† F: TTT AAA AGA AGC ATT CAA GGA CAT AAT G 3.75
R: CGG TGA AGG GCG CAC TG 3.75
F — forward; R — reverse; *GAPDH — glyceraldehyde 3-phosphate dehydrogenase; †ERa — estrogen receptor a; ††ERb — estrogen receptor b
Table 2. Comparison of the estrogen receptors expression in the vesico-vaginal and recto-vaginal fascia tissues between
the studied groups and with relation to POP status
ERa expression# p ERb expression# p ERa/ERb ratio p
Pre-menopausal with POP 2.4 (0.2–4.5) 0.013 0.48 (0.4–2.0) 0.05 12.4 (5.2–116.3) 0.087
(n = 4, S = 8)
Pre-menopausal without POP 0.2 (0.1–0.36) 2.4 (1.1–6.1) 0.77 (0.21–2.2)
(n = 5, S = 10)
Post-menopausal with POP 3.4 (1.1–5.9) 0.69* 1.14 (0.06–4.4) 0.82* 29.6 (9.1–41) 0.65*
(n = 12, S = 24)
Post-menopausal without POP 2.1 (0.8–5.9) 1.13 (0.09–5.6) 10.8 (1.0–62)
(n = 9, S = 18)
All groups with POP 3.3 (1.1–4.5) 0.032 1.1 (0.5–2.0) 0.18* 27.3 (9.1–41) 0.035
(n = 16, S = 32)
All groups without POP 0.36 (0.2–2.9) 2.2 (1.1–5.6) 2.2 (0.8–13.7)
(n = 14, S = 28)
All groups pre-menopausal 0.25 (0.2–2.4) 0.006 1.1 (0.7–4.9) 0.55* 1.92 (0.7–12.4) 0.026
(n = 9, S = 18)
All groups post-menopausal 3.2 (1.0–6.0) 2.1 (0.6–2.7) 22.1 (7.3–46.9)
(n = 21, S = 42)
n — number of patients; S — number of biopsy specimens; #calculated using the standard curves for ERa or ERb and normalized by the level of
GAPDH mRNA and by correction factors: 10–2 and 10–3 for the ERa and ERb expressions respectively ; *non significant
contrast, there were no differences in ERa expres-
sion in pre-menopausal women with POP compared
to post-menopausal women with POP; both groups
had relatively high levels of ERa mRNA in the stud-
ied tissues. The expression of ERb did not differ be-
fore and after menopause, when all studied women
were analyzed, or after stratification by POP status.
Discussion
The pathogenesis of POP is multifactorial, although
estrogen activity and the quality of connective tissue
seem to play crucial roles. The clinical course of pa-
tients with symptomatic pelvic organ prolapse clearly
suggests that POP development is promoted mostly by
a hypoestrogenic environment [5]. Yet, estrogen activity
is dependent not only on serum estrogen level, but also
on the expression of estrogen receptors. Additionally,
there are coregulators and other transcriptional factors
that have an effect on the estrogen dependent pathway.
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Numerous experiments have revealed the recip-
rocal relations between estrogens and connective tis-
sue. Estrogens and ERs regulate most of the genes
that encode growth factors engaged in the regulation
of the synthesis of extracellular matrix. Alterations in
the quantity and quality of collagen, morphology of
connective tissue after menopause, and experimen-
tal evidence that estrogen modulates the collagen
metabolism, strongly indicate the involvement of es-
trogens in the pathogenesis of pelvic organ prolapse
[12]. It is also believed that the appearance of pro-
lapse and mechanical stretch disturb the fibroblast’s
ability to maintain the cytoskeleton architecture and
quality of the extracellular matrix [13]. In addition,
estrogen has been shown to decrease tissue-degrad-
ing matrix metalloproteinases in fibroblasts derived
from pelvic floor connective tissue. Estrogen recep-
tors, ERa and ERb, have been found to be involved
in the regulation of estrogen action in human skin
fibroblasts [14]. Thus, the effect of estrogens in con-
nective tissue as a target organ depends not only on
the exposing levels of estrogen, but also on the intra-
cellular system of estrogen signaling — expression of
ERs and their coregulators.
Although it seems reasonable that estrogen im-
proves the mechanical integrity of the pelvic floor tis-
sues, there is insufficient data to support estrogen as
a therapy for POP. Reay et al. [15] described decreased
thickness and resilience of the uterosacral ligaments
removed at hysterectomy from post-menopausal
Figure 1. ERa and ERb expression in connective tissue of vesico-vaginal and recto-vaginal fascias (median, 1–3 quartile)
in pre-menopausal women with vs. without POP
Figure 2. ERa and ERb expression in connective tissue of vesico-vaginal and recto-vaginal fascias (median, 1–3 quartile)
in post-menopausal women with vs. without POP
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women without hormone therapy when compared
with pre-menopausal women. In a rhesus macaque
model, it was shown that estrogen therapy increases
expression of cystatin C, an inhibitor of collagen pro-
teases [16, 17]. Vaginal collagen content is determined
by the balance between the synthesis and degrada-
tion of the collagen. Previous studies have identified
ERs in the nuclei of connective tissue and the smooth
muscle cells of the bladder trigone, urethra, vaginal
mucosa, levator ani stroma and uterosacral ligaments
[18, 19]. The cardinal and uterosacral ligaments play
a crucial role in supporting the uterus in its normal
position. Serum estrogen levels and ER values have
been found to be significantly lower in the uterine
ligaments of pre-menopausal women with POP
[20, 21]. However, there was no difference in ER val-
ues among post-menopausal women with or without
POP when only subtype a of ER was analyzed [20].
Ewies et al. [22] studied the changes in gonadal ste-
roid receptors in the cardinal ligaments of prolapsed
uterus. Immunohistochemical analysis of the cardi-
nal ligaments showed 1.5–2.5 times increased expres-
sion of ERa in women with POP compared to pa-
tients without POP. Additionally, the expression of
ERb was twice as high in pre-menopausal women
without POP compared to pre-menopausal women
with POP, and there was no significant difference be-
tween both post-menopausal groups.
In vitro studies show that synthesis of ERs is reg-
ulated by SERMs and estradiol. In this setting, it is
Figure 4. Comparison of ERa/ERb ratio in women with vs. without POP in pre- and post-menopausal women and in
all studied groups
Figure 3. ERa and ERb expression in connective tissue of vesico-vaginal and recto-vaginal fascias (median, 1–3 quartile)
with vs. without POP in all studied groups
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reasonable to anticipate that the expression of ERs
varies depending on the status of menopause. Since
both estrogen receptors, ERa and ERb, are present
in the vesico-vaginal and recto-vaginal fascias, it is
possible to modulate the expression of ERs by either
the estrogens or the selective estrogen receptor mod-
ulators. SERMs such as levormeloxifene and idox-
ifene, increase the risk of pelvic organ relaxation and
POP was reported to the American Food and Drug
Administration (FDA) as an adverse event associat-
ed with both drugs [9, 10]. Current analysis, based on
data obtained from post-menopausal women treated
with raloxifene, demonstrates that raloxifene was as-
sociated with a 50% reduction in the risk of surgery
for pelvic floor relaxation in women treated for up to
three years [8]. In another analysis, raloxifene was not
found to have contributed to pelvic floor relaxation
[23]. This data raises the interesting hypothesis that
raloxifene may actually contribute to a reduction in
the incidence of pelvic floor relaxation, which could
be a reflection of estrogen agonist activities on the
tissues of the pelvic floor [8, 24]. The mechanism by
which raloxifene might affect pelvic floor relaxation
unfortunately is still unclear. The presence of ERs in
connective tissues makes the pelvic floor a target for
estrogens and SERMs. The remodeling of the pelvic
connective tissue is likely to be concerned with aging
and menopause. Collagen metabolism associated with
the menopause has been observed in bones and skin
[25, 26]. Since abnormal collagen metabolism has been
observed in the vaginal tissues of women with geni-
tourinary prolapse, the agents that positively affect
collagen turnover may restore pelvic tone and reduce
the incidence of pelvic floor relaxation. Although no
data yet supports a remodeling effect of raloxifene in
pelvic floor tissues, it is well known that raloxifene de-
creases collagen turnover in the skeleton, an effect that
may contribute in part to the 30–50% reduction in risk
for vertebral fracture in post-menopausal osteoporot-
ic women on raloxifene therapy [27, 28].
Our results demonstrated higher expression of
ERa and higher ERa/ERb ratio in post-menopausal
women compared to pre-menopausal women and in
all groups presenting POP. The results did not achieve
statistical significance for the post-menopausal wom-
en presenting POP and it could be explained by the
higher expression of ERa and ERa/ERb ratio in all
post-menopausal women and groups’ size. The ex-
pression of ERb was statistically lower in pre-meno-
pausal women with POP compared to pre-menopaus-
al women without POP and there was no difference
between the ERb expressions in post-menopausal
women with regards to POP status. The results in the
present study, although preliminary, demonstrate dif-
ferent expression of ERs concentration in pre-meno-
pausal and post-menopausal women and an alteration
in ERs expression with regards to POP status. It is
clear that higher ERa/ERb ratio is related to POP
and it is more pronounced in the pre-menopausal
group. Therefore, it makes us wonder if the observed
quantitative change could participate in the patho-
genesis of the development of POP.
The interpretation of our results meets several
difficulties. Basically, it is well known that the pro-
cesses of transcription and translation are not equal-
ly efficient. Furthermore, the stability of mRNAs and
proteins is different. Hence, it is obvious that mRNA
levels cannot precisely parallel the protein expression
and reflect actual receptor status. On the other hand,
the evaluation of ERa and ERb mRNA expression
levels enables the analysis of factors that were pre-
sumably implicated in the regulation of gene expres-
sion. Several methodological shortcomings in this
study must be recognized. The lack of baseline data
around the obstetric history of patients and other clin-
ical risk factors for POP prevented us from clinical
comparison between the groups. An additional weak-
ness of this analysis concerns the number of patients
recruited for this study, which is rather small. How-
ever, two biopsy specimens were obtained from each
patient and the results were statistically significant.
We believe that this preliminary basic science work
can contribute to continuous research and further
understanding of the pathophysiology of POP. Find-
ing the role of estrogen in the progression of pelvic
organ prolapse is a promising field, since it might be
the key for future therapy.
Conclusions
Higher ERa/ERb ratio was found to be related to
pelvic organ prolapse status in pre-menopausal and
in post-menopausal women, although it was more
pronounced in the pre-menopausal group presenting
POP. Larger studies are required in order to strength-
en our results.
Taking all the data into consideration, we cannot
state whether the alteration in the expression of ERs
is the cause or the result of the pelvic organ prolapse.
The effects of treatment using raloxifene on POP are
still not consistent, and further investigations are
needed in order to show an exact mechanism with
protective effect on the pelvic floor. Since there are
many local factors responsible for the transmission of
estrogen signals, individual expression of ERs in the
pelvic floor probably influences the results of treatment
with SERMs. Nowadays, we believe that the challenge
is to discover a SERM which would have a contracep-
tive effect, would decrease the risk of breast cancer and
finally would decrease the risk of pelvic organ prolapse.
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